United Kingdom Liquid Biopsy Market By Offering (Testing Service, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reactions (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles, Others), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region, Competition Forecast & Opportunities 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

The United Kingdom Liquid Biopsy Market is anticipated to grow at a significant rate in the projected period of 2024-2028. Liquid biopsy has emerged as a groundbreaking diagnostic tool in the field of oncology, enabling non-invasive detection and monitoring of various types of cancer. The United Kingdom has been at the forefront of embracing this innovative technology, revolutionizing cancer detection and treatment strategies.

Cancer remains a significant healthcare challenge in the United Kingdom, with an increasing incidence and mortality rate. Conventional tissue biopsies, while effective, are invasive, time-consuming, and often provide limited information due to tumor heterogeneity. Liquid biopsy offers a promising alternative, allowing the detection and monitoring of cancer through the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in blood or other bodily fluids.

With a few uses already approved by the U.S. Food and Drug Administration (FDA), liquid biopsy is a relatively new test with a number of potentially groundbreaking applications in the treatment of cancer. Its advantages are still being studied. Because of its potential to assist healthcare professionals in diagnosing and monitoring cancer with a straightforward blood test, liquid biopsy tests are an active area of research and development. Liquid biopsy tests are currently being developed to do things that traditional biopsy techniques cannot, such as detecting cancer before a tumor has formed. Even so, more investigation is required to comprehend the potential applications of liquid biopsy. In specific circumstances, they can assist in the diagnosis of certain cancers and guide treatment choices. They might have a lot more applications in the future, leading to the growth of the United Kingdom Liquid Biopsy Market.

Furthermore, liquid biopsy enables real-time monitoring of treatment response, detection of minimal residual disease, and identification of treatment-resistant mutations, facilitating personalized treatment approaches for patients. This is expected to grow the United Kingdom Liquid Biopsy Market in the forecast period. According to Cancer Research UK, lung cancer affects about 46,700 people annually in the United Kingdom alone. Sadly, only 1 in 20 people will live for 10 years or more, and this number has not decreased over the past ten years.

Moreover, collaborations between academic institutions, healthcare providers, and industry players are fostering innovation and driving the adoption of liquid biopsy across the United Kingdom. The National Health Service (NHS) plays a vital role in facilitating the integration of liquid biopsy into routine clinical practice, ensuring equitable access and improved patient outcomes, thus augmenting the growth of the United Kingdom Liquid Biopsy Market.


High Efficiency of Liquid Biopsy spur its demand in United Kingdom

The field of diagnostics has witnessed significant advancements in recent years, with liquid biopsy emerging as a powerful tool for non-invasive cancer detection and monitoring. In the United Kingdom, liquid biopsy has gained traction due to its high efficiency and potential to revolutionize the landscape of cancer diagnostics, which is expected to propel the growth of United Kingdom Liquid Biopsy Market. Traditional cancer diagnostics often involve invasive procedures such as tissue biopsies, which can be uncomfortable and carry associated risks. Liquid biopsy, on the other hand, offers a minimally invasive alternative by analyzing various biomarkers present in bodily fluids like blood, urine, and cerebrospinal fluid. These biomarkers include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs, among others. By monitoring changes in biomarker levels over time, liquid biopsy facilitates real-time assessment of treatment response and disease progression. This dynamic monitoring enables clinicians to make informed decisions regarding treatment adjustments or modifications, leading to the growth of United Kingdom Liquid Biopsy Market. Additionally, liquid biopsy also eliminates the need for invasive surgical procedures, reducing patient discomfort and recovery time. It also allows for repeated testing, enabling longitudinal monitoring of the disease without subjecting patients to multiple invasive procedures. Liquid biopsy provides a comprehensive molecular profile of the tumor, offering insights into its genetic alterations and identifying potential therapeutic targets. This information aids in the selection of appropriate treatment options, improving patient outcomes, which is expected to propel the growth of United Kingdom Liquid Biopsy Market. The of United Kingdom government has recognized the potential of liquid biopsy in advancing cancer diagnostics and has allocated significant funding for research and development in this area. As per the Research Cancer Research Fund, in 2019, 3,87,820 cases of cancer were diagnosed in United Kingdom. Government support and initiatives have created a favorable environment for the growth of the liquid biopsy market.  Collaboration between academic institutions, research organizations, and industry players has facilitated knowledge exchange, development of standardized protocols, and validation of liquid biopsy tests. Such collaborations have accelerated the translation of liquid biopsy from research to clinical applications, hence booming the United Kingdom Liquid Biopsy Market.

Growing Demand for Polymerase Chain Reaction (PCR) Technology drives United Kingdom Liquid Biopsy Market

The United Kingdom's liquid biopsy market is witnessing a significant surge in demand, primarily driven by the growing adoption of polymerase chain reaction (PCR) technology. PCR has emerged as a powerful tool within the liquid biopsy field, enabling highly sensitive and specific detection of genetic alterations in circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). The technique amplifies specific DNA sequences, allowing for the detection of minute quantities of genetic material associated with tumors. This capability has revolutionized cancer diagnostics and monitoring, offering several advantages over traditional tissue biopsies, leading to the growth of United Kingdom Liquid Biopsy market. One of the main drivers of the growing demand for PCR-based liquid biopsies in the UK is the increasing recognition of their potential for early cancer detection. Traditional tissue biopsies are invasive, require skilled personnel, and often face challenges in obtaining sufficient tissue samples. Liquid biopsies, on the other hand, provide a minimally invasive alternative that can be easily repeated over time to monitor disease progression and treatment response. The advent of targeted therapies and personalized medicine has further propelled the adoption of liquid biopsies in the UK. PCR-based liquid biopsies enable the identification of specific genetic mutations or alterations in tumor DNA, guiding treatment decisions and helping to optimize patient outcomes. By providing real-time information on the genomic landscape of tumors, liquid biopsies contribute to precision medicine approaches, allowing for more effective and tailored therapies. As per Office for National Statistics, in 2021, compared to 10.0% in 2020, the total current healthcare expenditure increased in real terms by 7.1% after accounting for the effects of inflation on the economy as a whole. The United Kingdom has been at the forefront of adopting innovative healthcare technologies, and the growing demand for PCR-based liquid biopsies is a testament to this trend. Leading diagnostic companies and research institutions in the country are actively investing in liquid biopsy research and development, aiming to expand the range of detectable biomarkers and improve the sensitivity and accuracy of the technology, which is expected to grow the United Kingdom Liquid Biopsy Market.

Recent Developments

  • In 2020, According to a news release from the NIH National Cancer Institute, the US Food and Drug Administration (FDA) expanded its clearance for two liquid biopsy tests in United Kingdom—Guardant Health's Guardant360 CDx and Foundation Medicine's FoundationOne Liquid CDx—for use as companion diagnostic tests and for general tumor profiling for specific non-small cell lung, prostate, breast, and ovarian cancers.

Mergers and Acquisitions

In March 2023, University of Birmingham collaborated with Nonacus which is a liquid biopsy cancer detection and screening company. The urine-based molecular test, known as GALEAS Bladder, that was launched at the Annual Meeting of the European Association of Urology, can more effectively diagnose bladder cancer and lessen the need for invasive cystoscopies by detecting it rapidly and precisely.

Market Segmentation

United Kingdom Liquid Biopsy Market is segmented into Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, Region and Competitive Landscape. Based on Offering, the United Kingdom Liquid Biopsy Market is divided into Testing Service, Kits, Platform and Other Consumables. Based on Technology, the market is categorized into Polymerase Chain Reactions, Next Generation Sequencing and Others. Based on Workflow, the United Kingdom Liquid Biopsy Market is categorized into Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management. Based on Sample, the market is categorized into Blood, Urine, Saliva and Others. Based on Circulating Biomarker, the market is categorized into Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles and Others. Based on Application, the market is categorized into Oncological and non-Oncological. Based on End User, the market is categorized into Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies. Based on region, the United Kingdom Liquid Biopsy Market is segmented into Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.

Company Profiles

F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc, PerkinElmer Inc., Illumina, Inc., QIAGEN NV, Dxcover Limited, Abcodia Ltd, Sysmex Corporation, Bio-Rad Laboratories, Inc are some of the key players in the United Kingdom Liquid Biopsy Market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company shares, competitive landscape, growth factors, and trends

Segments covered

Offering

Technology

Workflow

Sample

Circulating Biomarker

Application

End User

Region

Country scope

Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands

Key companies profiled

F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc, PerkinElmer Inc., Illumina, Inc., QIAGEN NV, Dxcover Limited, Abcodia Ltd, Sysmex Corporation, Bio-Rad Laboratories, Inc

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs.  Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, United Kingdom Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

  • United Kingdom Liquid Biopsy Market, By Offering:
    • Testing Service
    • Kits
    • Platform
    • Other Consumables
  • United Kingdom Liquid Biopsy Market, By Technology:
    • Polymerase Chain Reactions
    • Next Generation Sequencing
    • Others
  • United Kingdom Liquid Biopsy Market, By Workflow:
    • Sample Preparation
    • Library Preparation
    • Sequencing
    • Data Analysis & Management
  • United Kingdom Liquid Biopsy Market, By Sample:
    • Blood
    • Urine
    • Saliva
    • Others
  • United Kingdom Liquid Biopsy Market, By Circulating Biomarker:
    • Circulating Tumor Cells (CTCs)
    • Cell Free Nucleic Acids
    • Exosomes & Extracellular Vesicles
    • Others
  • United Kingdom Liquid Biopsy Market, By Application:
    • Oncological
    • non-Oncological
  • United Kingdom Liquid Biopsy Market, By End User:
    • Clinical Laboratories
    • Academic & Research Institutes
    • Pharmaceutical & Biotechnology Companies
  • United Kingdom Liquid Biopsy Market, By Region:
    • Scotland
    • South-East
    • London
    • South-West
    • East-Anglia
    • Yorkshire & Humberside
    • East Midlands

Competitive landscape

Company Profiles: Detailed analysis of the major companies in United Kingdom Liquid Biopsy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

United Kingdom Liquid Biopsy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customers

5.    United Kingdom Liquid Biopsy Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Offering (Testing Service, Kits, Platform, Other Consumables)

5.2.2.     By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)

5.2.3.     By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

5.2.4.     By Sample (Blood, Urine, Saliva, Others)

5.2.5.     By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

5.2.6.     By Application (Oncological v/s non-Oncological)

5.2.6.1.         By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)

5.2.6.2.         By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

5.2.7.     By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

5.2.8.     By Company (2022)

5.2.9.     By Region

5.3.  Market Map

6.    United Kingdom Liquid Biopsy Testing Service Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Technology

6.2.2.     By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

6.2.3.     By Sample (Blood, Urine, Saliva, Others)

6.2.4.     By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

6.2.5.     By Application (Oncological v/s non-Oncological)

6.2.5.1.         By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)

6.2.5.2.         By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

6.2.6.     By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

7.    United Kingdom Liquid Biopsy Kits Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Technology

7.2.2.     By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

7.2.3.     By Sample (Blood, Urine, Saliva, Others)

7.2.4.     By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

7.2.5.     By Application (Oncological v/s non-Oncological)

7.2.5.1.         By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)

7.2.5.2.         By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

7.2.6.     By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

8.    United Kingdom Liquid Biopsy Platform Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Technology

8.2.2.     By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

8.2.3.     By Sample (Blood, Urine, Saliva, Others)

8.2.4.     By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

8.2.5.     By Application (Oncological v/s non-Oncological)

8.2.5.1.         By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)

8.2.5.2.         By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

8.2.6.     By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

9.    Market Dynamics

9.1.     Drivers

9.2.     Challenges

10.  Market Trends & Developments

10.1.    Mergers & Acquisitions

10.2.    Recent Trends & Developments

10.3.    New Type Launches

11.  United Kingdom Liquid Biopsy Market:  SWOT Analysis

12.  Porters Five Forces Analysis

12.1.    Competition in the Industry

12.2.    Potential of New Entrants

12.3.    Power of Suppliers

12.4.    Power of Customers

12.5.    Threat of Substitute Types

13.  PESTLE Analysis

14.  Policy & Regulatory Landscape

15.  United Kingdom Economic Profile

16.  Competitive Landscape

16.1.    F. Hoffmann-La Roche AG

16.2.    Thermo Fisher Scientific, Inc

16.3.    PerkinElmer Inc.

16.4.    Illumina, Inc.

16.5.    QIAGEN NV

17.   Strategic Recommendations

18. About us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

Increasing prevalence of cancer and PCR technologies are driving the growth of United Kingdom Liquid Biopsy market.

down-arrow

United Kingdom Liquid Biopsy Market was analyzed for the historical period of 2018 to 2021. While the base year was 2022, estimation for the year 2023 was calculated and the market growth was further forecast for 2024 to 2028.

down-arrow

Liquid Biopsy is a blood test that can identify cancerous tumor indications such as tumor cells and cancer cell DNA.

down-arrow

F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc, PerkinElmer Inc., Illumina, Inc., QIAGEN NV are some of the key players in the United Kingdom Liquid Biopsy Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

United Kingdom Liquid Biopsy Market to be Dominated by Oncological Application Through 2028

Oct, 2023

Increasing prevalence of cancer and PCR technologies are expected to drive the United Kingdom Liquid Biopsy Market in the forecast period, 2024-2028.

Why Choose Us